Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Elevance Health Inc.
Elevance Health Inc. News
Dec 20, 2024 - zacks.com
Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?
Dec 12, 2024 - seekingalpha.com
Santa's Stunning Stocking Surprises: 5 High Yield Blue-Chip Bargains For 2025
Dec 11, 2024 - globenewswire.com
Robbins LLP Informs Elevance Health Inc. Stockholders that it is Investigating the Officers and Directors of ELV to Determine if They Breached Fiduciary Duties Owed to Shareholders
Dec 11, 2024 - seekingalpha.com
Elevance Health: A Quality Underpriced Stock Returning To Health
Elevance Health Inc. Quantitative Score
About Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Elevance Health Inc. Earnings & Revenue
Elevance Health Inc. Financials
Table Compare
Compare ELV metrics with: | |||
|---|---|---|---|
Earnings & Growth | ELV | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ELV | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ELV | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ELV | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Elevance Health Inc. Income
Elevance Health Inc. Balance Sheet
Elevance Health Inc. Cash Flow
Elevance Health Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Buy |
| Return on Assets | Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Elevance Health Inc. Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 6.5200 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2024-12-20 | 1.63 | Quarterly |
| 2024-09-25 | 1.63 | Quarterly |
| 2024-06-25 | 1.63 | Quarterly |
| 2024-03-22 | 1.63 | Quarterly |
| 2023-12-21 | 1.48 | Quarterly |
Elevance Health Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Elevance Health Inc. Executives
| Name | Role |
|---|---|
| Ms. Gail Koziara Boudreaux | President, Chief Executive Officer & Director |
| Mr. Peter David Haytaian Esq. | Executive Vice President and President of Carelon & CarelonRx |
| Ms. Felicia Farr Norwood | Executive Vice President & President of Government Health Benefits |
| Mr. Blair Williams Todt | Executive Vice President and Chief Legal & Administrative Officer |
| Mr. Mark Bradley Kaye | Executive Vice President & Chief Financial Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Gail Koziara Boudreaux | President, Chief Executive Officer & Director | Female | 1961 | 6.09M |
| Mr. Peter David Haytaian Esq. | Executive Vice President and President of Carelon & CarelonRx | Male | 1970 | 2.68M |
| Ms. Felicia Farr Norwood | Executive Vice President & President of Government Health Benefits | Female | 1960 | 2.18M |
| Mr. Blair Williams Todt | Executive Vice President and Chief Legal & Administrative Officer | Male | 1968 | 2.11M |
| Mr. Mark Bradley Kaye | Executive Vice President & Chief Financial Officer | Male | 1980 | 659.18K |
Elevance Health Inc. Insider Trades
| Date | 1 Nov |
| Name | Kendrick Charles Morgan JR |
| Role | EVP & President, Commercial |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 846 |
| Date | 1 Nov |
| Name | Kendrick Charles Morgan JR |
| Role | EVP & President, Commercial |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 1710 |
| Date | 1 Nov |
| Name | Haytaian Peter D |
| Role | EVP & Pres Carelon & CarelonRx |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 1649 |
| Date | 1 Nov |
| Name | Haytaian Peter D |
| Role | EVP & Pres Carelon & CarelonRx |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 3799 |
| Date | 18 Oct |
| Name | Kendrick Charles Morgan JR |
| Role | EVP & President, Commercial |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 7417 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 1 Nov | Kendrick Charles Morgan JR | EVP & President, Commercial | Disposed | F-InKind | 846 |
| 1 Nov | Kendrick Charles Morgan JR | EVP & President, Commercial | Acquired | A-Award | 1710 |
| 1 Nov | Haytaian Peter D | EVP & Pres Carelon & CarelonRx | Disposed | F-InKind | 1649 |
| 1 Nov | Haytaian Peter D | EVP & Pres Carelon & CarelonRx | Acquired | A-Award | 3799 |
| 18 Oct | Kendrick Charles Morgan JR | EVP & President, Commercial | Disposed | S-Sale | 7417 |